Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Next-generation immunotherapy biomarkers require simultaneous analysis of multiple cell types, spatial interactions, and immunoregulatory molecules.
• Current methods may lack the resolution or comprehensiveness for detailed tissue analysis.

Purpose of the Study:

• To introduce a comprehensive platform, AstroPath, for high-fidelity, single-cell resolution multispectral imaging and mapping of tumor tissue.
• To identify pretreatment tissue-based biomarkers predictive of response to anti-programmed cell death-1 (PD-1) therapy in melanoma.

Main Methods:

• Development of the AstroPath platform integrating image analysis and data handling from astronomy.
• Application of the platform using six markers on pretreatment melanoma specimens.
• Validation of identified predictive signatures in an independent patient cohort.

Main Results:

• AstroPath enabled high-fidelity, single-cell resolution analysis of tumor tissue.
• Key predictive features for anti-PD-1 therapy response were identified, including CD163+PD-L1- myeloid cells and CD8+FoxP3+PD-1low/mid T cells.
• A predictive signature combining these features stratified long-term survival in melanoma patients.

Conclusions:

• The AstroPath platform offers a powerful tool for discovering novel tissue-based biomarkers in cancer immunotherapy.
• Specific immune cell populations and their characteristics in pretreatment melanoma predict response to anti-PD-1 blockade.
• This approach facilitates personalized treatment strategies for melanoma patients receiving immunotherapy.